gene

EP300

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about EP300: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

575Connections

1Hypotheses

2Analyses

50Outgoing

50Incoming

0Experiments

4Debates

Summary

EP300 is a gene implicated in neurodegeneration research. Key relationships include: associated with, therapeutic target, regulates. Associated with Aging, Als, Alzheimer. Connected to 390 entities in the SciDEX knowledge graph.

View on Wiki →

No AI portrait yet

🧬 Gene Info

Gene Symbol	EP300
Chromosome	22q13.2
Protein Type	Transferase
Function	is an important component in the neurobiology of neurodegenerative diseases.
Primary Expression	Ubiquitous, highest in brain
Molecular Weight	300 kDa
Amino Acids	414 aa
Pathways	NF-κB
GeneCards	EP300
Human Protein Atlas	EP300
Associated Diseases	Als, Alzheimer, Autoimmune, Cancer, Carcinoma
Known Drugs/Compounds	Acetyl-CoA, rapamycin
Interactions	ACAT1, AMPK, AND, ATG, AUTOPHAGY, BRD4
SciDEX Hypotheses	p300/CBP-dependent K280 acetylation nucleates path
KG Connections	575 knowledge graph edges
Databases	GeneCards UniProt NCBI Gene HPA STRING

Wiki Pages (2)

Knowledge base pages for this entity

Canonical Page

EP300 Gene

gene · 608 words

→

EP300 Protein (p300)

protein · 917 words

→

Pathway Diagram

graph TD
    EP300["EP300"] -->|"Regulates"| histone_H2B_acetylation["histone H2B acetylation"]
    EP300["EP300"] -->|"Associated With"| Tumor["Tumor"]
    EP300["EP300"] -->|"Associated With"| Parkinson["Parkinson"]
    EP300["EP300"] -->|"Therapeutic Target"| Glioblastoma["Glioblastoma"]
    EP300["EP300"] -->|"Therapeutic Target"| Cancer["Cancer"]
    EP300["EP300"] -->|"Therapeutic Target"| Ms["Ms"]
    EP300["EP300"] -->|"Therapeutic Target"| Fibrosis["Fibrosis"]
    EP300["EP300"] -->|"Therapeutic Target"| Hepatitis["Hepatitis"]
    OPTN["OPTN"] -->|"Associated With"| EP300["EP300"]
    ULK1["ULK1"] -->|"Associated With"| EP300["EP300"]
    CALCOCO2["CALCOCO2"] -->|"Associated With"| EP300["EP300"]
    HSPA8["HSPA8"] -->|"Associated With"| EP300["EP300"]
    STX17["STX17"] -->|"Associated With"| EP300["EP300"]
    style EP300 fill:#8d4900,color:#e0e0e0
    style histone_H2B_acetylation fill:#1b5e20,color:#e0e0e0
    style Tumor fill:#b71c1c,color:#e0e0e0
    style Parkinson fill:#b71c1c,color:#e0e0e0
    style Glioblastoma fill:#b71c1c,color:#e0e0e0
    style Cancer fill:#b71c1c,color:#e0e0e0
    style Ms fill:#b71c1c,color:#e0e0e0
    style Fibrosis fill:#b71c1c,color:#e0e0e0
    style Hepatitis fill:#b71c1c,color:#e0e0e0
    style OPTN fill:#8d4900,color:#e0e0e0
    style ULK1 fill:#8d4900,color:#e0e0e0
    style CALCOCO2 fill:#8d4900,color:#e0e0e0
    style HSPA8 fill:#8d4900,color:#e0e0e0
    style STX17 fill:#8d4900,color:#e0e0e0

Outgoing (373)

Target	Relation	Type	Str
Histone Acetylation	regulates	process	0.90
RPTOR	phosphorylates	protein	0.85
ESR1	interacts_with	protein	0.80
Cancer	therapeutic_target	disease	0.75
Tumor	expressed_in	disease	0.75
Cancer	expressed_in	disease	0.75
K280 acetylated tau	causes	protein	0.70
TAU Acetylation	regulates	phenotype	0.70
epigenetic regulation	participates_in	pathway	0.70
MAPK signaling	participates_in	pathway	0.70
NF-κB target gene promoters	activates	pathway	0.70
SIRT1	interacts_with	gene	0.70
histone H2B acetylation	regulates	process	0.70
Als	regulates	disease	0.65
Cancer	activates	disease	0.65
Schizophrenia	interacts_with	disease	0.65
Aging	activates	disease	0.65
Cancer	regulates	disease	0.65
Leukemia	activates	disease	0.65
Carcinoma	regulates	disease	0.65
Cancer	associated_with	disease	0.65
Stroke	associated_with	disease	0.65
Aging	therapeutic_target	disease	0.65
Tumor	activates	disease	0.65
Ms	activates	disease	0.65
Tumor	inhibits	disease	0.65
Migraine	associated_with	disease	0.65
Carcinoma	activates	disease	0.65
Leukemia	therapeutic_target	disease	0.65
Hypertension	activates	disease	0.65
Carcinoma	associated_with	disease	0.65
Glioblastoma	associated_with	disease	0.65
Ms	therapeutic_target	disease	0.65
Alzheimer	associated_with	disease	0.65
Fibrosis	associated_with	disease	0.65
Carcinoma	therapeutic_target	disease	0.65
Hepatitis	therapeutic_target	disease	0.65
Als	therapeutic_target	disease	0.65
Parkinson	associated_with	disease	0.65
Tumor	therapeutic_target	disease	0.65
Dementia	interacts_with	disease	0.65
Hepatitis	associated_with	disease	0.65
Obesity	associated_with	disease	0.65
Diabetes	associated_with	disease	0.65
Multiple Sclerosis	associated_with	disease	0.65
Als	associated_with	disease	0.65
Leukemia	associated_with	disease	0.65
Autoimmune	associated_with	disease	0.65
Ms	regulates	disease	0.65
Tumor	associated_with	disease	0.65

Incoming (202)

Source	Relation	Type	Str
CBX3	interacts_with	protein	0.93
Acetyl-CoA	activates	compound	0.90
CBX3	binds	gene	0.90
P53	expressed_in	gene	0.70
CANCER	expressed_in	gene	0.70
AKT	co_discussed	gene	0.65
AXIN2	regulates	gene	0.60
CBP	regulates	gene	0.60
CDH5	regulates	gene	0.60
MAP1LC3	associated_with	gene	0.60
AMPK	co_discussed	gene	0.60
APOPTOSIS	co_discussed	gene	0.60
AUTOPHAGY	co_discussed	gene	0.60
LYSOSOME	regulates	gene	0.60
PARKINSON	associated_with	gene	0.60
ATG	associated_with	gene	0.60
ACETYL-COA	associated_with	gene	0.60
APOPTOSIS	associated_with	gene	0.60
AMPK	associated_with	gene	0.60
P53	associated_with	gene	0.60
GSK3	associated_with	gene	0.60
RUBCNL	associated_with	gene	0.60
CREB	interacts_with	gene	0.60
ACTR2	regulates	gene	0.60
APC	regulates	gene	0.60
EGFR	targets	gene	0.60
ULK1	associated_with	gene	0.60
HSPA8	associated_with	gene	0.60
STX17	associated_with	gene	0.60
SQSTM1	associated_with	gene	0.60
RB1CC1	associated_with	gene	0.60
HDAC6	associated_with	gene	0.60
SIRT1	associated_with	gene	0.60
LC3	associated_with	gene	0.60
SNAP29	associated_with	gene	0.60
RB1	associated_with	gene	0.60
KAT5	associated_with	gene	0.60
WIPI2	associated_with	gene	0.60
ALDH1A1	therapeutic_target	gene	0.60
CREBBP	co_discussed	gene	0.60
CREBBP	associated_with	gene	0.60
NBR1	associated_with	gene	0.60
GAPDH	associated_with	gene	0.60
HSP70	associated_with	gene	0.60
NDP52	associated_with	gene	0.60
VAMP8	associated_with	gene	0.60
PIK3C3	associated_with	gene	0.60
TFEB	associated_with	gene	0.60
RB1	therapeutic_target	gene	0.60
FGF20	therapeutic_target	gene	0.60

Targeting Hypotheses (1)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
p300/CBP-dependent K280 acetylation nucleates pathogenic tau	0.455	neurodegeneration	Which specific post-translational modifi

Mentioning Analyses (2)

Scientific analyses that reference this entity

How do different microglial subtypes (DAM vs inflammatory vs homeostatic) transi

neurodegeneration | 2026-04-16 | 4 hypotheses Top: 0.887

Which specific post-translational modifications on pathological tau create drugg

neurodegeneration | 2026-04-09 | 3 hypotheses Top: 0.455

Experiments (0)

Experimental studies targeting or related to this entity

Experiment	Type	Disease	Score	Feasibility	Model	Status	Est. Cost
No experiments found

Related Papers (0)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year	Citations
No papers found

Debates (4)

Multi-agent debates referencing this entity

Related Research

Hypotheses and analyses mentioning EP300 in their description or question text

No additional research found

EP300

Understanding Entity Pages

Summary

Wiki Pages (2)

EP300 Gene

EP300 Protein (p300)

Pathway Diagram

Outgoing (373)

Incoming (202)

Targeting Hypotheses (1)

Mentioning Analyses (2)

How do different microglial subtypes (DAM vs inflammatory vs homeostatic) transi

Which specific post-translational modifications on pathological tau create drugg

Experiments (0)

Related Papers (0)

Debates (4)

The debate framework mentioned multiple microglial subtypes but no analysis was

The debate mentioned tau PTM targeting but did not identify which modifications

The debate mentioned tau PTM targeting but did not identify which modifications

Which specific post-translational modifications on pathological tau create drugg

Related Research